Tarsus Pharmaceuticals's total assets for Q3 2025 were $534.56M, an increase of 7.99% from the previous quarter. TARS total liabilities were $199.48M for the fiscal quarter, a 22.85% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.